Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: The results are in

Journal of Clinical Oncology

Volumn 27, Issue 19, 2009, Pages 3082-3084

  O'Connell, Michael J ^a  

^a NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EDITORIAL; HUMAN; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; COLON TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLONIC NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67650296948     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.2919     Document Type: Editorial

References (13)

1. Van Cutsem E, Labianca R, Bodoky G, et al: Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117-3125, 2009
2. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
3. Ychou M, Raoul JL, Douillard JY, et al: A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20:674-680, 2009
4. Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 25:3456-3461, 2007
5. Grothey A, Sargent D: FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol 23:3311-3313, 2005
6. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
7. O'Connell MJ, Campbell ME, Richard M, et al: Survival following recurrence in stage II and III colon cancer: Findings from the ACCENT data set. J Clin Oncol 26:2336-2341, 2008
8. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II, and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007
9. Sharif S, O'Connell MJ, Yothers G, et al: FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest 26:956-963, 2008
10. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875, 2005
11. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
12. Goldberg RM, Sargent DJ, Morton R, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
13. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 352-358, 1990